Please check your internet connection and try again.
# Aztreonam-Avibactam (Emblaveo)
## Overview
Aztreonam-avibactam is an antibiotic combination of a monobactam (aztreonam) and a non-$\beta$-lactam $\beta$-lactamase inhibitor (avibactam). It is specifically engineered to overcome resistance mediated by metallo-$\beta$-lactamases (MBLs), such as NDM, as well as Class A and C $\beta$-lactamases.
## Primary Indications
Treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI, including pyelonephritis), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) caused by aerobic Gram-negative organisms where MBL-producing strains are suspected.
## Adult Dosing
* **Standard Dose:** 2 grams (aztreonam) / 500 mg (avibactam) administered via IV infusion over 2 hours.
* **Frequency:** Every 8 hours.
* **Duration:** Generally 7–14 days based on the severity and site of infection.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use should be limited to off-label scenarios per institutional infectious disease consultation and local protocols.
## Dose Adjustments
* **Renal Impairment:** Requires dose adjustment based on estimated Glomerular Filtration Rate (eGFR).
* eGFR 30–50 mL/min: 2g/500mg every 12 hours.
* eGFR 15–30 mL/min: 1g/250mg every 12 hours.
* eGFR <15 mL/min (including hemodialysis): 1g/250mg every 24 hours.
* **Hepatic Impairment:** No dose adjustment is required.
## Contraindications
Hypersensitivity to the active substances (aztreonam or avibactam) or any component of the formulation. Caution in patients with a history of severe hypersensitivity to other $\beta$-lactams, though cross-reactivity with aztreonam is rare.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, increased transaminases (ALT/AST).
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (including anaphylaxis), and potential for seizures (particularly with excessive dosing in renal impairment).
## Key Drug Interactions
* **Probenecid:** May increase serum concentrations of aztreonam by inhibiting renal tubular secretion; co-administration is generally not recommended.
* **Other Antibiotics:** Minimal significant pharmacokinetic interactions; however, avoid mixing in the same line with other antibiotics due to physical incompatibility.
## Monitoring
* **Renal Function:** Monitor eGFR regularly to ensure appropriate dose adjustments.
* **Liver Function:** Monitor ALT/AST levels during prolonged therapy.
* **Infection Response:** Clinical signs/symptoms, inflammatory markers (CRP/PCT), and microbiological clearance.
## Clinical Pearls
* **MBL Activity:** This agent is a "niche" drug designed specifically to target carbapenem-resistant Enterobacterales (CRE) that produce MBLs. It is not effective against Gram-positive or anaerobic organisms.
* **Infusion Time:** The 2-hour infusion time is critical to achieving the necessary pharmacodynamic exposure (time above the minimum inhibitory concentration).
* **Availability:** Availability varies significantly by region (currently authorized in the EU and other territories; status in the US may be subject to different regulatory pathways). Always confirm availability via local pharmacy services.
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always consult the most recent product monograph, institutional infectious disease specialists, and current clinical guidelines before prescribing or administering medication.*
